{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurodegenerative+Disease%2C+Hereditary&page=31",
    "query": {
      "condition": "Neurodegenerative Disease, Hereditary",
      "page": 31
    },
    "page_size": 10
  },
  "pagination": {
    "page": 31,
    "page_size": 10,
    "total_count": 1148,
    "total_pages": 115,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurodegenerative+Disease%2C+Hereditary&page=32&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurodegenerative+Disease%2C+Hereditary&page=30&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T00:58:22.591Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04768296",
      "title": "Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Berzosertib",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2021-03-29",
      "completion_date": "2023-07-21",
      "has_results": true,
      "last_update_posted_date": "2024-09-26",
      "last_synced_at": "2026-10-23T00:58:22.591Z",
      "location_count": 12,
      "location_summary": "Santa Rosa, California • Topeka, Kansas • Bethesda, Maryland + 8 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Topeka",
          "state": "Kansas"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04768296"
    },
    {
      "nct_id": "NCT01590888",
      "title": "Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Huntington Disease"
      ],
      "interventions": [
        {
          "name": "PBT2",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prana Biotechnology Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 109,
      "start_date": "2012-04",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2016-07-18",
      "last_synced_at": "2026-10-23T00:58:22.591Z",
      "location_count": 14,
      "location_summary": "San Diego, California • Englewood, Colorado • Farmington, Connecticut + 10 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01590888"
    },
    {
      "nct_id": "NCT01358474",
      "title": "Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Parkinson Disease",
        "Gaucher Disease",
        "Idiopathic Rapid Eye Movement Sleep Disorder"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 56,
      "start_date": "2011-07",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2019-04-18",
      "last_synced_at": "2026-10-23T00:58:22.591Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01358474"
    },
    {
      "nct_id": "NCT03943290",
      "title": "Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Facioscapulohumeral Muscular Dystrophy",
        "Charcot-Marie-Tooth Disease"
      ],
      "interventions": [
        {
          "name": "ACE-083",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2019-05-10",
      "completion_date": "2020-03-11",
      "has_results": true,
      "last_update_posted_date": "2022-09-26",
      "last_synced_at": "2026-10-23T00:58:22.591Z",
      "location_count": 19,
      "location_summary": "Orange, California • Sacramento, California • Aurora, Colorado + 16 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03943290"
    },
    {
      "nct_id": "NCT01873924",
      "title": "Clinical and Neuropsychological Investigations in Batten Disease",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neuronal Ceroid Lipofuscinosis",
        "Neuronal Ceroid Lipofuscinosis CLN1",
        "Neuronal Ceroid Lipofuscinosis CLN2",
        "Neuronal Ceroid Lipofuscinosis CLN3",
        "Neuronal Ceroid Lipofuscinosis CLN5",
        "Neuronal Ceroid Lipofuscinosis CLN6",
        "Neuronal Ceroid Lipofuscinosis CLN7",
        "Neuronal Ceroid Lipofuscinosis CLN8",
        "Neuronal Ceroid Lipofuscinosis CLN10",
        "Batten Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 500,
      "start_date": "2004-08",
      "completion_date": "2035-08",
      "has_results": false,
      "last_update_posted_date": "2025-09-12",
      "last_synced_at": "2026-10-23T00:58:22.591Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01873924"
    },
    {
      "nct_id": "NCT02728388",
      "title": "Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NEUROFIBROMATOSIS 1"
      ],
      "interventions": [
        {
          "name": "aminolevulinic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Donald Basel",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "14 Years to 30 Years"
      },
      "enrollment_count": 30,
      "start_date": "2016-09-16",
      "completion_date": "2026-03-28",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-23T00:58:22.591Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02728388"
    },
    {
      "nct_id": "NCT01795859",
      "title": "First Time Use of SD-809 in Huntington Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chorea"
      ],
      "interventions": [
        {
          "name": "SD-809",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2013-08-05",
      "completion_date": "2014-12-05",
      "has_results": true,
      "last_update_posted_date": "2017-09-20",
      "last_synced_at": "2026-10-23T00:58:22.591Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01795859"
    },
    {
      "nct_id": "NCT00537680",
      "title": "Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Friedreich's Ataxia"
      ],
      "interventions": [
        {
          "name": "Idebenone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santhera Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "8 Years to 17 Years"
      },
      "enrollment_count": 70,
      "start_date": "2007-12",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2023-07-11",
      "last_synced_at": "2026-10-23T00:58:22.591Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00537680"
    },
    {
      "nct_id": "NCT01018056",
      "title": "Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Tourette Syndrome"
      ],
      "interventions": [
        {
          "name": "D-serine",
          "type": "DRUG"
        },
        {
          "name": "Riluzole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "8 Years to 17 Years"
      },
      "enrollment_count": 39,
      "start_date": "2009-11",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2018-01-30",
      "last_synced_at": "2026-10-23T00:58:22.591Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01018056"
    },
    {
      "nct_id": "NCT05469373",
      "title": "ESIS in Pediatric DRE",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Sarah Katie Ihnen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 86,
      "start_date": "2022-02-17",
      "completion_date": "2028-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-23T00:58:22.591Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05469373"
    }
  ]
}